title: Effect of pyrazinamide and probenecid on peritoneal urate transport kinetics during continuous ambulatory peritoneal dialysis.
abstract: OBJECTIVE
  We administered pyrazinamide (PZA) and probenecid (PB) --two well-known modulators of urate transport via the proximal tubules - to evaluate their impact on urate transport through the peritoneal membrane and to clarify mechanisms affecting peritoneal transport.
  
  
  METHODS
  A continuous ambulatory peritoneal dialysis (CAPD) unit in 2nd Hospital of IKA (Social Services Institute), Greece.
  
  
  METHODS
  In 20 stable CAPD patients, on the study day, a 4-hour, 2-L, 1.36% glucose exchange was performed (control exchange). Pyrazinamide 3 g was given orally and another identical exchange was performed (study exchange). The same protocol was repeated with 2 g PB. KtN, peritoneal clearances of urea, creatinine, and urate for each exchange, and mass transfer area coefficients (MTAC) for the three solutes and their dialysate-to-plasma concentration (D/P) ratios were used to estimate peritoneal transport.
  
  
  RESULTS
  Administration of PZA resulted in decreased clearances and MTAC values for the three solutes. The D/P ratio decreased significantly only for urate, indicating a more intense influence of PZA on urate. After PB administration, clearances of urea, creatinine, and urate were increased. MTAC and DIP ratio increased significantly only for urate (p < 0.05), demonstrating an action similar to that exerted on renal tubules.
  
  
  CONCLUSIONS
  These findings provide evidence that unrestricted diffusion is not the only transport mechanism in the case of urate, and demonstrate the existence of an active mechanism in peritoneal urate transport with a reabsorptive and, probably, a secretive component that resembles that of renal tubule urate transport. Attention should be given in the case of CAPD patients undergoing antituberculous (PZA) treatment: it might have a negative impact on urea, creatinine, and urate peritoneal transport rates.
authors.affiliation: Renal Department, Second Hospital of IKA, Thessaloniki, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Spaia
authors.forename: I
authors.initials: I
authors.lastname: Magoula
authors.forename: G
authors.initials: G
authors.lastname: Tsapas
authors.forename: G
authors.initials: G
authors.lastname: Vayonas
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000187:drug effects* / Q000378:metabolism*; D011339:Probenecid / Q000494:pharmacology*; D011718:Pyrazinamide / Q000494:pharmacology*; D014527:Uric Acid / Q000378:metabolism*; D014528:Uricosuric Agents / Q000494:pharmacology*
chemical_list: D014528:Uricosuric Agents; D014527:Uric Acid; D011718:Pyrazinamide; D011339:Probenecid